Home
AAVantgarde Bio

AAVantgarde Bio Market Share Analysis for August 2026

AAVantgarde è una società internazionale di biotecnologie in fase clinica, con sede in Italia, che ha sviluppato due piattaforme esclusive basate su vettori virali adeno-associati (AAV)

Industry: N/A

Domainaavantgarde.com

Year Founded--

Employees51 - 200

Annual Revenue--

AAVantgarde Bio

AAVantgarde Bio (including company regionals)

aavantgarde.com

See more website traffic and engagement information

Total visits to AAVantgarde Bio's top domains

Understand AAVantgarde Bio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

aavantgarde.com6.3K

See more with Sales Intelligence

Avg. visit duration in AAVantgarde Bio's top domains

Analyze AAVantgarde Bio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

aavantgarde.com00:00:37

See more with Sales Intelligence

Avg. pageviews on AAVantgarde Bio's top domains

See how AAVantgarde Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

aavantgarde.com2.00

See more with Sales Intelligence

AAVantgarde Bio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by AAVantgarde Bio

These are the website technologies, by industry, used by AAVantgarde Bio top domains

Marketing (3)

Google Marketing Platform

Email Services (2)

Microsoft Exchange Online

Mobile (2)

Meta Viewport

Advertising (1)

DoubleClick

More Technologies

5

See all

News & Signals from AAVantgarde Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAAVantgarde Bio S.r.l. hired Megan Zoschg Canniere as Chief Regulatory & Quality officer on Sep 1st '26.AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality officer.

NewsAAVantgarde Bio S.r.l. is developing pipeline of gene therapies targeting inherited retinal diseases.AAVantgarde is developing a pipeline of gene therapies targeting inherited retinal diseases, utilizing proprietary adeno-associated viral (AAV) vector platforms designed for large gene delivery.

NewsAAVantgarde Bio S.r.l. attended event 44th Annual J.P. Morgan Healthcare Conference on Jan 12th '26.LONDON / MILAN, January 8, 2026 - AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026 in San Francisco, California.